Shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) have been assigned a consensus rating of “Hold” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.35.

ALPN has been the subject of several analyst reports. Zacks Investment Research lowered shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. ValuEngine lowered shares of Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of Nivalis Therapeutics in a report on Thursday, July 27th. They issued a “buy” rating and a $17.00 target price for the company.

Nivalis Therapeutics (ALPN) traded up 1.48% during midday trading on Friday, hitting $8.90. 66,723 shares of the stock were exchanged. Nivalis Therapeutics has a 1-year low of $7.20 and a 1-year high of $37.40. The company’s 50 day moving average is $8.81 and its 200-day moving average is $9.71. The stock’s market cap is $11.93 million.

In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology purchased 17,806 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $40,063.50. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 9.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Nivalis Therapeutics, Inc. (ALPN) Given Average Recommendation of “Hold” by Analysts” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/nivalis-therapeutics-inc-alpn-given-average-recommendation-of-hold-by-analysts/1547007.html.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.